NCT02815670View on ClinicalTrials.gov

Reversal Dabigatran Anticoagulant Effect With Idarucizumab

PHASE3CompletedINTERVENTIONAL
Enrollment

1

Participants

Timeline

Start Date

September 7, 2016

Primary Completion Date

October 19, 2019

Study Completion Date

October 19, 2019

Conditions
Hemorrhage
Interventions
DRUG

Idarucizumab

Trial Locations (2)

420138

Children Rep.Clin.Hosp of MoH,Cardio Vas.surgery Dept, Kazan, Kazan'

625021

Regional Clin.Hosp.1,Congen.heart defects&child.Cardiol.dept, Tyumen

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY